DMT Shows Rapid Antidepressant Effects in Trial

A Phase IIa randomized, placebo-controlled clinical trial, led by researchers at Imperial College London and sponsored by Cybin (formerly Cybin UK, now Helus), demonstrated that a single intravenous dose of dimethyltryptamine (DMT) rapidly and significantly reduced depressive symptoms in patients with moderate-to-severe major depressive disorder. The study, involving 34 participants who had not responded to conventional treatments, showed sustained improvements for up to three months, and in some cases, six months. Unlike longer-acting psychedelics like Psilocybin or LSD (LSD), Dimethyltryptamine (DMT)'s effects last only minutes, potentially making it a more practical and cost-effective treatment option in clinical settings. The treatment was generally well-tolerated with mild side effects. These early-stage findings, published in Nature Medicine, suggest that short-acting psychedelics warrant further investigation as a potential therapy for treatment-resistant depression, although larger and longer trials are needed.